Blue Horizon International does not offer or provide medical treatment or see patients within the United States. Our cellular and exosome products are investigational and are not approved by the U.S. FDA. This website is for informational and educational purposes only and is not medical advice.

Style Sampler

Layout Style

Patterns for Boxed Mode

Backgrounds for Boxed Mode

All fields are required.

Close Appointment form

Brian Mehling, MD presented at the Annual Congress of Society for Brain Mapping & Therapeutics in Los Angeles

  • Home
  • Brian Mehling, MD presented at the Annual Congress of Society for Brain Mapping & Therapeutics in Los Angeles
Brian Mehling, MD presented at the Annual Congress of Society for Brain Mapping & Therapeutics in Los Angeles

No Comments

World leading translational neuroscience foundation highlighted the pioneering scientific, technological, advocacy, and policy work at the Ritz Carlton/JW Marriott in Downtown LA on July 10, 2021

The conference was the first in-person major medical conference in California after the state reopened.
Dr. Brian Mehling is the founder and chief medical officer of BHI Therapeutic Sciences. He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.
Dr. Mehling presented two talks in two sessions: “Session in Innovation in Spine Surgery” where his talk title was ” Umbilical Cord Blood Stem Cell Therapy for Spinal Cord Injury.”
The objective of this retrospective cohort study was to analyze the muscle, nerve, urinary, and gastrointestinal function in subjects with spinal cord injury, treated with either human umbilical cord blood-derived mononuclear cells or conventional therapy. “Allogeneic umbilical cord blood mononuclear cell therapy in 30 subjects with spinal cord injury showed significant improvement in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group,” Dr. Mehling said.
The second session was in Neurovascular Disorders and Dr.Mehling talk’s title was “Stem Cells and Stroke Recovery: A Retrospective Study.” Dr. Mehling presented the results of a study using Human umbilical cord blood cell therapy to treat stroke. Ninety-seven research subjects with ischemic and hemorrhagic stroke showed significant improvement of mobility of upper and lower extremities, muscle strength of upper and lower limbs and neurological function after therapy.

In addition, Dr.Mehling co-chaired a stem cell session (Session A26 – Stem Cell).

BHI Therapeutic Sciences (BHITS) supports investigational research and education in stem cell and regenerative medicine using ethically sourced cord blood cells.
Brain Mapping Foundation (BMF) was established in 2003 to help fast-tracking diagnostics and therapeutics for wounded soldiers, veterans, and civilians with neurological, spine, and neuro-psychiatric disorders. Since then, the organization has been pioneering lifesaving therapeutics and introducing trailblazing initiatives such as Neuroscience20 (Brain20, Spine20, Mental20) and Brain Technology and Innovation Park (BTIP) while celebrating pioneers in the fields.

Media Contact
Doreen Santora
201-342-7662
dsantora@bluehorizoninternational.com

  • Share This

About the author

Related Posts

Submit a comment

Your email address will not be published. Required fields are marked *

Leave a Reply

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>